排序方式: 共有4条查询结果,搜索用时 15 毫秒
1
1.
BACKGROUND: Research on patented technology plays a real and important role in the technological development and industrial application.
OBJECTIVE: To investigate the current patented technologies concerning biodegradable magnesium and magnesium alloy vascular stents.
METHODS: We searched the patent applications for biodegradable magnesium and magnesium alloy stents in China, and analyzed relevant information in the following aspects: application trend, authorization trend, applicant geographical distribution, distribution of applicant types, sub-sector patented technology, and patented technology of major applicants. Afterwards, recommendations for patent application in this field could be given.
RESULTS AND CONCLUSION: In China, Chinese applicants occupy a dominant position in the patent applications for biodegradable magnesium and magnesium alloy stents, and hot technologies in various sub-sectors are highlighted. Unfortunately, more patented technologies have not achieved a real breakthrough in the application. 相似文献
2.
目的 研究头孢克肟颗粒在健康人体内的药代动力学及相对生物利用度。方法 2 0名健康男性志愿者随机交叉单剂量口服 2 0 0mg头孢克肟及参比制剂 ;采用HPLC法测定血药浓度。结果 受试及参比制剂药动学参数分别为Cmax(3 15± 0 82 )和 (3 17± 0 84)mg·L- 1,tmax(4 6± 0 7)和 (5 1± 0 5)h ,t1/ 2 (4 64± 1 44)和 (4 18± 1 0 9)h ,AUC0~t(2 8 54± 8 68)和(2 7 81± 8 3 8)h·mg·L- 1,MRT(8 90± 2 0 3 )和 (8 78± 0 99)。经统计分析 ,两种制剂的药物动力学参数均无显著性差异 ;头孢克肟颗粒的相对生物利用度为 (10 3 4± 14 7) %。结论 两种制剂具有生物等效性 相似文献
3.
目的 研究头孢克肟颗粒在健康人体内的药代动力学及相对生物利用度。方法 20名健康男性志愿者随机交叉单剂量口服200mg头孢克肟及参比制剂;采用HPLC法测定血药浓度。结果 受试及参比制剂药动学参数分别为Cmax(3.15±0.82)和(3.17±0.84)mg·L-1,tmax(4.6±0.7)和(5.1±0.5)h,t1/2(4.64±1.44)和(4.18±1.09)h,AUC0~t(28.54±8.68)和(27.81±8.38)h·mg·L-1,MRT(8.90±2.03)和(8.78±0.99)。经统计分析,两种制剂的药物动力学参数均无显著性差异;头孢克肟颗粒的相对生物利用度为(103.4±14.7)%。结论 两种制剂具有生物等效性。 相似文献
4.
1